IQGAP2 is a member of IQGAPs scaffolding protein family. It has been reported as a tumor suppressor in various cancers, as well as, an oncogene in some cancers, suggesting organ specific role. Need to identify therapeutic targets which function in ER/PR independent way, prompted us to explore role of IQGAP2 in molecular mechanism in breast cancer, which was completely unknown. In vitro studies in estrogen receptor positive breast cancer cell line (MCF7) showed that low IQGAP2 expression results in increased cell proliferation, migration and invasion of cells whereas an opposite effect was observed with ectopic expression of 
Introduction
Breast cancer is at the top of all cancer incidences in women all around the world. According to SEER, 268,600 new cases of female breast cancer is estimated by the end of 2019 in US population [1] . Despite the advancement in breast tumor therapies, this is the second highest cause of cancer deaths, in women of developed countries [2] [3] [4] . Although the survival rate of breast cancer patients has improved, long-term survival still remains low due to drug resistance and relapse of metastasis [5] . Many genes have been recognized which have role in initiation or progression of breast cancer [4, [6] [7] [8] but lacunae in understanding of pathogenesis leaves a lot of scope to identify additional players, especially the one which can work independent of breast cancer molecular subtype.
IQGAPs (IQ Motif Containing GTPase Activating Proteins) are a class of scaffolding proteins and are evolutionarily conserved from lower to the higher eukaryotes [9] . Three members of this family namely, IQGAP1, IQGAP2 and IQGAP3, share high similarity at five conserved domains [10] . Despite the presence of similar domains, they show diverse cellular functions [9] . IQGAP1 and IQGAP3 have been found to be upregulated in many cancers and promote tumor growth and metastasis [11] [12] [13] [14] [15] , whereas the role of IQGAP2 is not fully understood in cancers. Most of the reports showed a reduced expression of IQGAP2 in HCC, prostate, gastric and ovary cancer [16] [17] [18] [19] , suggesting it to be a tumor suppressor but in couple of studies it was found to be an oncogene too [20, 21] . Our previous work also showed reduced expression level of IQGAP2 in breast cancer, using Oncomine data analysis [22] . Based upon these observations we hypothesised that IQGAP2 might be implicated in breast cancer tumorigenesis as a tumor suppressor gene.
In this study, to find out if the role of IQGAP2 in breast cancer tumorigenesis is independent of molecular subtype, we first explored the effect of IQGAP2 expression level, on tumorigenic properties of ER/PR positive breast cancer cell line, followed by similar study in triple negative breast cancer cell line. We also explored the precise mechanism/pathway by which IQGAP2 regulates invasion and EMT events in vitro. Our findings provide a potential therapeutic target to inhibit breast cancer progression and metastasis.
Materials and Methods

Breast cancer patient sample collection
The archival, formalin-fixed paraffin-embedded (FFPE) tissue blocks of 95 breast cancer 
Immunohistochemistry
FFPE block of cancer and matched normal tissue of each patient, was cut into 5 µm thin sections and, placed on poly L-lysine coated glass slides. The sections were deparaffinized by heating slides at 80°C for 1 hour followed by rehydration as follows: Xylene-3 min (twice), 100% ethanol-3 min, 90% ethanol-3 min, 70% ethanol-3 min, 50% ethanol-3 min, water-2 min, and water-2 minutes. The epitope retrieval was performed, in citrate low pH (pH 6.8)
retrieval buffer, by heat induction. Blocking was done in Envision Peroxidase Blocker (Dako) for 15 minutes followed by incubation with 1:100 diluted IQGAP2 primary antibody (Abcam), for 1 hour at room temperature. Subsequently, the sections were incubated with Envision Flex HRP secondary antibody (Dako) for 30 minutes and color was developed using liquid DAB Substrate. Finally, the sections were counterstained with hematoxylin. Two pathologists (NP and NM) did reporting independently, to nullify biasness.
The reporting of IQGAP2 IHC data was done as per the Allred scoring system [23] . In brief, Allred score was calculated by adding the values of intensity score (0 for negative, 1 for weak, 2 for moderate and, 3 for strong) and proportion score (0 -no cells are IQGAP2 +ve, 1 -≤1% of cells are IQGAP2 +ve, 2 -1%-10% of cells are IQGAP2 +ve, 3 -11%-33% of cells are IQGAP2 +ve, 4 -34%-66% of cells are IQGAP2 +ve, 5 -67%-100% of cells are IQGAP2 +ve) of cells. For statistical analyses, the Allred scores of 0-2 were treated as negative or weak, 3-6 as moderate and, 7-8 as intense/strong expression levels. For correlation study among different histopathological parameters and IQGAP2 IHC score, Allred score were divided into two groups, scores of 0-2 were considered negative and scores of 3-8 were considered positive.
IHC in human breast cancer tissue arrays
We also determined the expression of IQGAP2 in human breast cancer tissue microarray (US BioMax, BC081120c). In this array, 5 µm sections of 100 breast cancer tumor tissues and 10 normal adjacent tissues of breast were available. The immunohistochemistry and scoring of this array was performed in same way as described in immunohistochemistry section.
Histopathological and clinical information of the patient i.e. age, histological grade, lymphnode status, TNM staging were supplied with the array.
Cell culture, plasmids and stable line preparation
The breast cancer cell lines, MCF7 and MDA-MB-468 were purchased from cell repository, NCCS, Pune, India. MCF7 were grown and maintained in DMEM (HiMedia) supplemented with 10% FBS (US origin, HiMedia), ampicillin (HiMedia, 100 IU/ml), streptomycin (HiMedia, 100 µg/ml) whereas MDA-MB-468 were maintained in RPMI (HiMedia)
supplemented with 10% FBS (US origin, HiMedia), ampicillin (HiMedia, 100 IU/ml), streptomycin (HiMedia, 100 µg/ml). The cells were cultured at 37°C in 5% CO2. ABI 7500 platform (Applied Biosystems) was used to perform the reaction. The experiment was conducted using three biological and three technical replicates. We used GAPDH as an internal control. Relative expression was calculated using the 2 −∆∆CT method. (1:10000, Sigma) and anti-rabbit (1:10000, Sigma) secondary antibodies were then incubated for 1 hour at room temperature followed by detection of bands by chemiluminescence in ChemiDoc XRS+ (Bio-Rad).
Cell proliferation assay
Cell proliferation assay was performed in 96 well plate using CellTiter 
Transwell cell migration and invasion assay
To perform transwell cell migration assay, we used transwell chambers of 8 μm pore diameter from Millipore. Briefly, 0.05×10 6 MCF7 cells (IQGAP2_Ex, IQGAP2_KD and their controls) and 0.01×10 6 MDA-MB-468 cells (IQGAP_KD and it's control) were seeded in 500 µl of 2% DMEM in the upper chamber of a 12-well plate and 1 ml of 10% DMEM was filled in the lower chamber. The cells were incubated for another 24 hours at 37°C in 5% CO2. After incubation, media was decanted and chambers were washed with 1X PBS buffer. Cells were fixed with 4% PFA for 10 minutes and permeabilised using absolute methanol (Merck) for 20 minutes. Cells were stained with 0.5% crystal violet or Giemsa (HiMedia) for 15 minutes. Cells from the upper chamber were wiped off using a cotton wipe and image was captured using 10X
objective lens of an upright bright field microscope (Olympus). Cells from five different fields were counted using NIH ImageJ software. The experiment was performed in triplicates.
For Transwell invasion assay, all steps were same as mentioned in transwell migration assay, except in the initial step, transwell chambers were coated with 100 μl of 1 mg/ml growth factor reduced matrigel (Corning).
Statistical analyses
Statistical analysis was performed using GraphPad Prism 6.0 Version (GraphPad Software Inc.), Microsoft excel and SPSS. For cell based assays, continuous data was presented as the mean ± standard error of the mean. Student's t-test (2-tailed, unpaired) was used to determine significant difference between the groups. For IHC data, significance of difference in distribution frequency of Allred scores, between tumor and control group, was determined using 2-tailed, chi-square test. Spearman correlation test was also used to determine correlation between clinicopathological parameters and Allred scores for IQGAP2 expression. P-value ≤ 0.05, was considered to be significant for all the tests.
Results
IQGAP2 expression doesn't correlate with breast cancer molecular subtype
To 
Reduced IQGAP2 expression promotes cell proliferation in ER/PR positive cells
Further, we used estrogen receptor positive cell line, MCF7 to check the effect of IQGAP2 expression levels on the rate of proliferation, which is one of the hallmarks of tumorigenesis.
We used MCF7 cells with stable ectopic expression and depletion of IQGAP2 ( Figure 1C) .
In MTT based cell proliferation assay, we observed that the MCF7 with IQGAP2 depletion 
IQGAP2 silencing promotes migration and invasion in ER/PR positive breast cancer cells and vice versa
The cell migratory property, which is another important property of cancer, was assessed using wound healing and transwell migration assay. As shown in figure 3 
Effect of reduced IQGAP2 expression on tumorigenic cell properties is irrespective of ER/PR status
To find out if the effect of IQGAP2 on cell proliferation, migration and invasion, is irrespective of molecular subtype of breast cancer, we used MDA-MB-468 cells, which are triple negative.
In MDA-MB-468 cell lines the endogenous level of IQGAP2 was very high ( Figure 1A ) hence we depleted IQGAP2 in these cells stably ( Figure 4A ).
In MDA 
IQGAP2 induces epithelial-mesenchymal transition (EMT) in breast cancer cells
To determine the underlying mechanisms of IQGAP2's role in tumorigenesis, we tested the effect of it's expression level on EMT; western blot analysis was performed to detect the expression of epithelial and mesenchymal protein markers. Our results showed that over expression of IQGAP2 reduces the expression of mesenchymal marker proteins: twist, and Ncadherin while it up-regulated epithelial marker, E-cadherin ( Figure 5A ). Conversely, MCF7 cells with reduced IQGAP2 levels, exhibited decreased E-cadherin expression, but increased expression of EMT markers, twist and N-cadherin. (Figure 5B ). Overall, these results suggest that increased expression of IQGAP2 can inhibit tumor invasion and metastasis by suppressing EMT.
IQGAP2 mediated EMT occurs via the MEK/ERK signalling pathways in MCF7 cells
MEK/ERK and PI3K/AKT signalling pathways play an important role in migration, invasion, and metastasis of cancer by regulating EMT; therefore, we investigated if IQGAP2 was capable of promoting EMT via the MEK/ERK and PI3K/AKT pathways in MCF7 cells. Firstly, we estimated the alteration of ERK and AKT. As shown in figure 5C , overexpression of IQGAP2, decreased phosphorylation of ERK but not AKT, while silencing of IQGAP2 expression, increased ERK phosphorylation but did not show a change in AKT phosphorylation. This data suggested that reduction in IQGAP2 was promoting EMT via MEK/ERK activation.
Further, to evaluate whether the effects of IQGAP2 on cell migration and invasion were dependent on the ERK pathway, MCF7 line with stable IQGAP2 knock down, was treated with ERK inhibitor (U0126) (Calbiochem) 10 µM for 30 min. Inhibition of ERK abrogated the higher invasion observed with IQGAP2 knock down, and there was no significant difference compared to control ( Figure 5D ). In addition, inhibition of ERK1/2 by U0126 reversed the effect on twist expression, that is up-regulation which was induced by IQGAP2 knockdown ( Figure 5E ). These results confirm that reduced IQGAP2 expression induces cell migration, invasion, and EMT through MEK/ERK signalling pathways. (Table 2) . In the current study, our immunohistochemistry results have shown that IQGAP2 is significantly reduced in a large proportion of breast cancer cases which is consistent with the RNA data analysed from Oncomine and TCGA database [22] . Invasion of a cancer to the proximate blood vessels and/or lymphatic system i.e. Lymphovascular invasion, is one of the leading event for metastasis and it is correlated with poor survivability of the patient [24] [25].
Here, we have observed that more patients with IQGAP2 negative or low expression were positive for lymphovascular invasion. According to AJCC TNM stage and grading system higher stage i.e. III and IV represents the highly invasive and metastasis condition of a cancer patient [26] . We have found that the negative or weak IQGAP2 expression had a higher frequency in patients with higher stages, III or IV, compared to patients with early stages of breast cancer and vice versa. Remarkably, we did not find a significant correlation among IQGAP2 expression and tumor size. Here, we suggest that the change in late stages of IQGAP2 affect migration and invasion (metastasis) more, rather than cell growth, which starts in the early stages of cancer. We also find a significant correlation of age with IQGAP2 expression;
there was higher frequency of IQGAP2 negative patients in ≤40 year group, suggesting that no/low expression of IQGAP2 exposes to cancer early. On the basis of the above correlation studies of IQGAP2 in breast cancer and the survival data published recently by our group [22] , present study suggests that IQGAP2 has a protective role and it functions as a tumor suppressor in breast cancer patients.
To validate the function of IQGAP2 on in-vitro breast cancer model, different cell lines representing specific molecular sub-type of breast cancer were investigated. Initially, endogenous expression of this gene at protein and RNA level was measured that did not show any specificity towards molecular sub-type. The ER/PR positive MCF7 cell lines on reduction of IQGAP2 level show increase tumorigenic properties i.e. increased cell proliferation, migration and invasion. The opposite trend was observed with ectopic expression of IQGAP2.
Two major pathways, ERK and AKT promote migration and invasion of ER/PR positive breast cancer [27] . Previous study has also shown the role IQGAP2 in AKT pathways in prostate cancer [17] . In our study knockdown of IQGAP2 in MCF7 activated MEK-ERK signalling pathways. Interestingly, we did not observe a change in AKT pathway. Earlier reports suggest that activation of MEK-ERK cascade leads to downregulation of E-cadherin [28] and upregulation of EMT markers, N-cadherin, twist, snail and slug [29] . In our study, we also observed the same trend. Reduction of IQGAP2, increases the expression levels of N-cadherin, twist and slug and reduces E-cadherin level. This effect gets rescue after ERK/MEK inhibitor treatment in IQGAP2_KD group. An opposite pattern was also observed when IQGAP2 ectopically expressed in MCF7.
We further checked functions of IQGAP2 in triple negative breast cancer cell line, MDA-MB-468. A similar tumorigenic property of IQGAP2 reduction was observed as MCF7. The reduction in IQGAP2 level increases the cell growth, migration and invasion properties of MDA-MB-468. Altogether, IQGAP2 reduction promotes cancer progression and metastasis irrespective of the molecular subtypes of breast cancer.
In conclusion, our study explored, for the first time, the overall expression pattern of IQGAP2 in breast cancer patients, the association of IQGAP2 with the histological parameters of breast cancer and the detailed mechanism behind IQGAP2 function in breast cancer development and progression. Our data indicates that reduced IQGAP2 expression promotes cell proliferation migration and invasion via. activation of ERK pathway and plays a crucial role in the development of breast cancer and hence it may be a potential therapeutic target in breast cancer.
